Abstract
GLP-1 receptor agonists (GLP-1RAs) may be associated with a reduced risk for atrial arrhythmias, a benefit that appears particularly significant for patients with type 2 diabetes mellitus (T2DM) and a history of myocardial infarction (MI). This meta-analysis evaluates the cardiovascular impact of these agents on heart rhythm, suggesting a protective effect for the heart's upper chambers while noting no significant impact on ventricular arrhythmias. Further studies are required to confirm the definitive anti-arrhythmic role of this drug class.
Introduction
Patients with Type 2 Diabetes Mellitus (T2DM) face elevated cardiovascular risks, especially following a Myocardial Infarction (MI). In this high-risk population, arrhythmias such as Atrial Fibrillation (AF) are critical predictors of heart failure and mortality. While GLP-1RAs (e.g., semaglutide, liraglutide) are established for glycemic control and general cardiovascular benefits, their specific effect on heart rhythms has remained controversial, with previous studies yielding inconsistent results. This paper addresses these contradictions by focusing on the subgroup of patients with both T2DM and a significant history of MI.
Methods
Researchers performed a systematic review and meta-analysis in accordance with PRISMA 2020 guidelines. A comprehensive search of PubMed, Embase, Cochrane Library, and Web of Science was conducted to identify Randomized Controlled Trials (RCTs) comparing GLP-1RAs to placebos.
A unique inclusion criterion was applied: trials were selected only if at least 30% of participants had a history of MI. This allowed for an indirect evaluation of the drug's effects on this specific high-risk cohort. Data were pooled using a random-effects model to determine Relative Risk (RR) and 95% Confidence Intervals (CI).
Datasets
The analysis included data from five major clinical trials encompassing 31,314 patients:
- ELIXA: Lixisenatide (82.6% MI history)
- HARMONY OUTCOMES: Albiglutide (47.1% MI history)
- LEADER: Liraglutide (30.7% MI history)
- SUSTAIN 6 & PIONEER 6: Semaglutide (32.5% and 36.1% MI history, respectively)
Results
The meta-analysis revealed a distinct localization of cardiovascular benefits:
- Atrial Arrhythmias: GLP-1RAs were associated with a 19% lower risk (RR 0.81, 95% CI 0.70–0.95) compared to placebo. Statistical heterogeneity was notably low ($I^2 = 0\%$), indicating consistent results across trials.
- Ventricular Arrhythmias: No statistically significant difference was observed (RR 1.26, 95% CI 0.87–1.80).
- Other Outcomes: No significant associations were found for atrioventricular block (AVB), sinus arrhythmia, or sudden cardiac arrest.
Discussion and Insights
The findings suggest that GLP-1RAs provide targeted protection for the atria. The authors hypothesize a "stretch" mechanism: post-MI, increased pressure in the left ventricle can stretch the left atrium, triggering electrical remodeling and fibrosis that leads to AF. GLP-1RAs may mitigate this by reducing ventricular pressure and oxidative stress.
Subgroup analysis highlighted Semaglutide as particularly effective, showing a 36% reduction in atrial arrhythmias and a 38% reduction in AF specifically. While other drugs in the class showed similar trends, they did not reach individual statistical significance in this specific analysis.
Limitations and Future Work
Several limitations should be considered:
- Indirect Evidence: The primary trials were designed to evaluate major adverse cardiovascular events (MACE), not arrhythmias specifically.
- Data Source: Arrhythmia events were typically identified from "Serious Adverse Events" reports rather than continuous monitoring, potentially missing asymptomatic cases.
- Statistical Power: Low event numbers for outcomes like cardiac arrest resulted in wide confidence intervals.
Future research should include dedicated RCTs using arrhythmia as a primary endpoint in T2DM and MI patients to determine if these benefits constitute a class-wide effect or are unique to specific agents like Semaglutide.
Summary updated